Equities research analysts forecast that bluebird bio Inc (NASDAQ:BLUE) will post ($2.88) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for bluebird bio’s earnings. The lowest EPS estimate is ($3.28) and the highest is ($2.42). bluebird bio posted earnings of ($1.73) per share in the same quarter last year, which indicates a negative year over year growth rate of 66.5%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 7th.
On average, analysts expect that bluebird bio will report full-year earnings of ($10.85) per share for the current financial year, with EPS estimates ranging from ($11.52) to ($9.39). For the next year, analysts anticipate that the company will report earnings of ($11.76) per share, with EPS estimates ranging from ($13.79) to ($10.00). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover bluebird bio.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($2.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.30) by ($0.61). bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The firm had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $10.68 million. During the same period last year, the company posted ($1.73) earnings per share. The business’s revenue for the quarter was down 53.3% compared to the same quarter last year.
Several analysts recently commented on BLUE shares. William Blair reissued a “buy” rating on shares of bluebird bio in a research report on Wednesday, September 5th. Gabelli started coverage on shares of bluebird bio in a research report on Thursday, July 12th. They set a “buy” rating and a $239.00 price objective on the stock. Cowen reissued a “buy” rating on shares of bluebird bio in a research report on Monday, August 6th. SunTrust Banks reissued a “buy” rating and set a $223.00 price objective on shares of bluebird bio in a research report on Friday, August 3rd. Finally, BMO Capital Markets reissued a “buy” rating and set a $208.00 price objective on shares of bluebird bio in a research report on Friday, August 3rd. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $212.21.
Shares of BLUE stock opened at $126.77 on Monday. bluebird bio has a one year low of $120.02 and a one year high of $236.17. The stock has a market cap of $7.91 billion, a P/E ratio of -16.44 and a beta of 1.89.
In other news, insider Alison Cecily Finger sold 259 shares of the firm’s stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $158.07, for a total transaction of $40,940.13. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Philip D. Gregory sold 1,800 shares of the firm’s stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $156.61, for a total transaction of $281,898.00. Following the sale, the insider now directly owns 33,471 shares in the company, valued at approximately $5,241,893.31. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,859 shares of company stock worth $10,029,606. Insiders own 3.00% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in BLUE. Tower Research Capital LLC TRC purchased a new position in shares of bluebird bio in the second quarter worth approximately $201,000. XR Securities LLC purchased a new position in shares of bluebird bio in the second quarter worth approximately $212,000. Laurel Wealth Advisors Inc. purchased a new position in shares of bluebird bio in the first quarter worth approximately $215,000. Atria Investments LLC purchased a new position in shares of bluebird bio in the third quarter worth approximately $216,000. Finally, First Republic Investment Management Inc. purchased a new position in shares of bluebird bio in the second quarter worth approximately $234,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Further Reading: Put Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.